66 results about "Ischemic myocardium" patented technology

The invention discloses a use of a derived polypeptide series of pigment epithelium derived factors in ischemic myocardium protection. The polypeptide is derived from the pigment epithelium derived factors, and every amino acid sequence in the polypeptide includes at least eighteen continuous amino acid residues. The PEDF derived functional peptide has good function advantages, and has remarkablecardiac muscle tissue capillary tube stabilization, vascular leakage prevention, myocardial cell protection and cardiac muscle tissue inflammation prevention effects.

The invention discloses a preparation method and application of a pyridazinone myocardial perfusion PET radiopharmaceutical. According to the invention, a large-dose initial 18F activity label is adopted, the precursor usage amount of a reaction, the reaction temperature and the purification HPLC condition are optimized, the reaction yield is improved, the preparation amount of [18F]Fmpp2 can reach 200 mCi, the chemical impurity amount is reduced, the radiochemical purity is high, and the key quality index is kept stable within 6 hours. A method for preparing a [18F]Fmpp2 solution for injection is improved, and the radiochemical purity and stability of the [18F]Fmpp2 are improved. The [18F]Fmpp2 prepared by the invention is subjected to miniature pig myocardial model PET imaging display; after the [18F]Fmpp2 is intravenously injected, the myocardial radioactive uptake is high, and the influence of peripheral organs on myocardial development is small; and normal myocardium, ischemic myocardium caused by chronic coronary artery stenosis and infarcted myocardium caused by acute coronary artery stenosis can be distinguished.

The invention provides, among other things, methods and systems for expanding CD133+ cells. The invention further provides methods and systems for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides methods and systems for directing differentiation of expanded CD133+ cells. The invention further provides methods and systems for treating a subject with differentiated cells in a subject in need thereof.

The invention relates to a focusing ultrasonic cavitation treatment instrument which is used for treating tumor, thrombolysis, ischemic myocardium and disease of prostate based on the cavitation effect of the ultrasonic contrast agent microvesicle. The focusing ultrasonic cavitation treatment instrument comprises a main control machine, two combined treatment probes, and a B ultrasonic machine with an ultrasonic focusing ultrasonic cavitation treatment instrument function. The focusing ultrasonic cavitation treatment instrument is mainly used for the partial area of the focus, and carries out non-invasive treatment on the tumor based on the cavitation effect of the microvesicle. The microvesicle can greatly improve the cavitation effect, so that the ultrasonic focusing positioning radiation with low power can be precisely carried out in the partial area of the focus, and the cavitation effect of the microvesicle within the vessel just can be activated within the partial area, and the capillaries in the tumor can be subject to embolism and damage, so as to achieve the purpose of 'starving' the tumor. The threshold for generating the cavitation is not met by the ultrasonic energy at the periphery of the focusing area, so that the cavitation effect is not generated, so that the path where the ultrasonic wave passes or the ambient tissue can not be damaged; and the functions of the common tissue and organs are protected.

A method for identifying the viability of ischemic myocardium of a patient. The method includes the steps of measuring in real-time the ischemic myocardium of a beating or non-beating heart. There is the step of determining in real-time whether the ischemic myocardium of the beating or non-beating heart is stunned or is nonviable. An apparatus for identifying the viability of ischemic myocardium of a patient's heart. The apparatus includes an electrode array having at least four electrodes for electrical communication with the heart which produces an array signal. The apparatus includes a processor portion in communication with the array which receives the array signal and determines in real-time whether the ischemic myocardium of the heart is stunned or is nonviable. An apparatus for analyzing living tissue. The apparatus includes an electrode array having at least four electrodes for electrical communication with the tissue which produces an array signal. The apparatus includes an admittance magnitude and phase detection circuit in communication with the array which receives the array signal from the array and produces a detection circuit signal corresponding to phase angle and magnitude of the array and signal. The apparatus includes a processor in communication with the detection circuit which receives the detection circuit signal and determines permittivity and conductivity of the tissue in real-time. A method for analyzing living tissue.

Methods and apparatus for preventing myocardial infarction, or lessening the size/severity of an evolving myocardial infarction, by cooling at least the affected area of the myocardium using an intravascular heat exchange catheter. The heat exchange catheter may be inserted into the vasculature (e.g., a vein) and advanced to a position wherein a heat exchanger on the catheter is located in or near the heart (e.g., within the vena cava near the patient's heart). Thereafter, the heat exchange catheter is used to cool the myocardium (or the entire body of the patient) to a temperature that effectively lessens the metabolic rate and/or oxygen consumption of the ischemic myocardial cells or otherwise protects the ischemic myocardium from undergoing irreversible damage or infarction.

In the field of biological medicines, a use of prourokinase (proUK) and variants thereof in facilitated percutaneous coronary intervention (PCI) in patients with acute myocardial infarction is provided. The use includes: within 6 hrs after a patient is afflicted with accurate myocardial infarction (AMI), firstly, performing thrombolytic therapy with proUK or variants thereof, and then, performing a PCI operation, to dredge the infarction related artery (IRA) as soon as possible, and re-establish an effective forward blood flow, such that an ischemic myocardium is reperfused. According to the present invention, the facilitated PCI for treatment of AMI with the proUK or variants thereof has an effect superior to that of direct PCI.

The invention provides a method for improving the survivability of old people mesenchymal stem cells after transplanting. According to the method, mesenchymal stem cells with passage stability obtained from the bone marrow of old people are put into a conventional culture medium in which 0.5mumol/L SRT1720, 5mM NAD+ and 20mM glutamine are added; pretreatment is performed for 24 hours; the obtained and processed mesenchymal stem cells are used for cell transplanting treatment. The method has the beneficial effects that for the SRT1720 pretreatment, the apoptosis of the old people mesenchymal stem cells under the stress condition can be inhibited through inhibiting an exogenous apoptosis path of the old people mesenchymal stem cells; after the transplanting of the mesenchymal stem cells subjected to the SRT1720 pretreatment, the survival rate in the ischemic myocardium is improved; the effect for treating ischemic cardiomyopathy is obviously improved.

An application of the active components extracted from chrysanthemum flower in preparing the medicines in the form of solid or liquid for treating the ischemic heart disease is disclosed.

The invention discloses a medicinal composition for treating coronary disease and a preparation method thereof. The medicinal composition is prepared from musk, bezoar, ginseng extracts, cinnamon, storax, borneol, toad venom, ground beetle and auxiliary materials. The medicinal composition has the effects of activating Yang based on aromatic herbs, inducing resuscitation and relieving pains, and tonifying vital energy and strengthening heart, is used for treating angina pectoris, choking sensation in chest and myocardial infarction caused by myocardial ischemia, and can be used in ischemic myocardium collateral revascularization and medicinal bypass of coronary disease.

The invention discloses a method for constructing an ordered ischemic-cardiomyocyte-mitochondria-targeting drug-loading (model drugs such as puerarin, baicalin, and the like respectively can act on ischemic cardiomyocyte mitochondria so as to treat myocardial ischemia reperfusion injury ) nanometer micelle, wherein the method comprises synthesizing a TPP-PEG-PE block copolymer, and preparing an ordered targeting drug-loaded nanometer micelle. According to the present invention, the puerarin drug is precisely delivered to ischemic cardiomyocyte mitochondria by using the ordered targeting drug-loaded nanometer micelle so as to provide the pharmacological effect, wherein the drug carrier is accumulated in the ischemic myocardium at the early stage of the infarct in a targeting manner throughthe EPR effect of the PEG-PE nanometer micelle, and the charge effect of the TPP cation mediates the drug carrier to enter the negatively charged cardiomyocyte mitochondria to deliver the puerarin andother drugs to the ischemic cardiomyocyte mitochondria in stages so as to achieve the precise administration.

The present invention relates to the treatment of coronary heart disease by revascularization therapy, and more particularly to the intramyocardial injection of a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 protein or a fragment of a recombinant fibroblast growth factor-1 protein, optionally, with a physiologic glue for inducing local neoangiogenesis in ischemic myocardium. Methods of producing the recombinant fibroblast growth factor 1 protein and fragments are also disclosed.

The invention belongs to the field of traditional Chinese medicines and particularly relates to a preparation method of total flavonoids of clematis filamentosa Dunn and application of the total flavonoids of clematis filamentosa Dunn to a drug for treating myocardial ischemia. The main technical scheme is as follows: whole dried herbs on the overground part of clematis filamentosa Dunn serving as a traditional Chinese medicine are extracted, chromatographically separated and purified to prepare the total flavonoids of clematis filamentosa Dunn, wherein the purity of the total flavonoids of clematis filamentosa Dunn is more than 85%. In-vitro and in-vivo pharmacological experiments prove that the prepared total flavonoids of clematis filamentosa Dunn can be used for treating myocardial ischemia, reducing blood viscosity and reducing platelet aggregation, and have a certain protecting effect for ischemic myocardium cells and a remarkable myocardial ischemia treating effect. The high-purity total flavonoids of clematis filamentosa Dunn are prepared from clematis filamentosa Dunn medicinal materials serving as raw materials through macroporous resin and silica gel chromatographic coupled separation, the total flavonoids of clematis filamentosa Dunn can be prepared into a preparation such as a tablet, a capsule, a dropping pill and a powder injection by adding auxiliary materials, and the preparation can be applied to treatment of myocardial ischemia diseases such as latent coronary heart disease, angina, myocardial infarction and ischemic cardiomyopathy. The preparation method disclosed by the invention is simple and stable in process and is easily produced in batches.

The invention relates to an injection agent for protecting ischemic myocardium and a preparation method of the injection. Injection emulsion is prepared from the following raw materials in parts by mass: 1 to 5 parts of N-SAHA (Suberoylanilide Hydroxamic Acid), 0.2 to 12.5 parts of emulsifying agent, 2 to 100 parts of oil for injection, 0.02 to 5 parts of solubilizer, 0.03 to 0.4 part of oleic acid, 0.4 to 12.5 parts of glycerinum and the balance of water for injection. The injection emulsion can be effectively used for increasing local drug concentration of the N-SAHA in lipophilic organs such as angiocarpy and/or tissues before cardiac interventional operation, increasing the bioavailability of the N-SAHA, reducing general side effects of the N-SAHA, realizing effective protection on myocardium under an ischemic or reperfusion injury state and reducing or avoiding the occurrence of myocardial infarction; meanwhile, a new optional dosage form is provided for application of the N-SAHAin treating cancer by the injection emulsion.

The invention discloses a stem cell drug fused with PNV targeted ischemic myocardial blood vessels. The stem cell drug comprises cardiovascular precursor stem cells, and platelet membrane nano-vesicles PNV are fused on the surfaces of the cardiovascular precursor stem cells. The platelet membrane nano-vesicles PNV are prepared by the aid of the biological characteristic that human platelet membrane glycoprotein receptors naturally target to ischemic myocardium and atherosclerosis ischemic blood vessels for homing, and the cardiovascular precursor stem cells are coated with the PNV to prepare the stem cell drug. The PNV reserves the glycoprotein receptors on platelet membranes and can sense various dangerous signal molecules, does not have a mechanism for triggering activated coagulation, is a natural and safe targeted navigation substance and can carry the vascular precursor stem cells to target to the ischemic myocardial blood vessels for homing, and the damaged myocardial blood vessels are accurately repaired. Two vascular precursor cells including Flk-1+ cells and adventitial peripheral cells (APC) are further adopted and matched with WJMSCs, and the vascular precursor cells canbe directly differentiated into blood vessels with a blood perfusion function.